Zone 2 Training for APOE4: Your Exact Heart Rate Targets For Maximum Brain Health

Two copies of APOE4. Does every memory lapse mean something, and would more testing help? Dr. Gayatri Devi explains why she starts with a cognitive baseline, not constant self-checking. Dr. Devi directs Park Avenue Neurology in New York and is Clinical Professor of Neurology and Psychiatry at the Zucker School of Medicine at Hofstra/Northwell. I went in with concerns Phoenix members had raised about memory lapses and testing before symptoms. I did not ask the submitted questions on camera. Several of those concerns still came up. WANT YOUR QUESTION IN THE NEXT INTERVIEW? Members can submit questions before future interviews. Not every question fits. Phoenix also helps you build your personal protocol, review your own blood tests and find support from other carriers. Apply to join Phoenix: https://apoe4.link/GayatriQnA1 RESOURCES → Brain Biomarker Guide: https://apoe4.link/GayatriQnA1G → Free newsletter: https://apoe4.link/GayatriQnA1N → Free Clinical Trial Engine: https://apoe4.link/GayatriQnA1C A NOTE ON WHAT THIS IS Educational, not medical advice or a product endorsement. Take this to your own clinician. APOE4 is a risk factor, not a diagnosis. KEY TAKEAWAYS 1. A useful baseline measures more than memory. Language, visual-spatial skills and switching tasks also matter. An age-average score may not reflect your own earlier ability. 2. Repeating tests can improve test familiarity. Dr. Devi tells her patients to leave at least a year between routine assessments. This is not a rule to delay care for new symptoms. 3. A positive p-tau217 result needs context. She discusses whether amyloid is present, not a person's odds of developing dementia. 4. She notes that most people in their 80s with amyloid are cognitively intact. That does not mean someone will never develop symptoms. Her amyloid case series is unpublished. 5. Her priorities include aerobic exercise, blood vessel health, sleep and stress. Her more proactive views on scans and treatment before symptoms go beyond the guidance and trial evidence she describes. QUESTIONS FOR YOUR CLINICIAN What would this test measure? How would you interpret it for someone like me? What would change after a positive, negative or unclear result? These are discussion prompts, not a testing or treatment protocol. Full sources and limits are in the original YouTube description. WHAT WE COVER 00:00 Teaser 01:10 Why a second APOE4 copy matters 02:34 What two copies of APOE4 means, and why age at discovery matters 05:22 What a proper baseline test includes 07:42 Practice effect: how often to retest 08:54 Biomarkers vs. real risk: why plaques don't always mean dementia 14:41 How reliable is the P-tau217 blood test? 16:01 Handling the anxiety: sleep and other no-brainer interventions 17:58 Amyloid scans for people without symptoms 20:08 The amyloid hypothesis and anti-amyloid drugs 24:17 ARIA brain bleed risk and slow dosing 26:48 Final advice from Dr. Devi 28:30 Outro: Kevin's three takeaways

Originally published on YouTube on 15 April 2026. Original video: https://www.youtube.com/watch?v=Xoq4DTX_YtM Free guide: The APOE4 Diet Playbook https://thephoenix.community/guides/diet-playbook What did the 2026 JAMA Network Open study actually find about meat and APOE4? I walk through the study, processed versus unprocessed meat, its limitations and what I am doing with the findings, alongside the broader research on lifestyle and cognition. RESOURCES Apply to join Phoenix: https://apoe4.link/Meat Essential APOE4 Guide: https://apoe4.link/MeatG Weekly Newsletter: https://apoe4.link/MeatN CHAPTERS 00:00 Introduction 01:16 What the Study Found 03:16 Processed vs Unprocessed Meat 04:55 Why This Doesn’t Prove Cause 05:20 Limits of this study 07:42 What Should APOE4 Carriers Eat? 11:06 Lifestyle Matters More 13:49 Conclusion ORIGINAL LINKS AND REFERENCES 1. Norgren J et al. "Meat Consumption and Cognitive Health by APOE Genotype." JAMA Network Open. 2026 https://doi.org/10.1001/jamanetworkopen.2026.6489 2. Jin X et al. "APOE e4 genotype and lifestyle with cognitive function." PLoS Med. 2021 https://doi.org/10.1371/journal.pmed.1003597 3. Zhong WF et al. "Combined effects on cognitive impairment with APOE consideration." Alzheimers Res Ther. 2025 https://doi.org/10.1186/s13195-025-01806-7 4. Moon SY et al. "SUPERBRAIN-MEET RCT." Alzheimers Dement. 2025 https://doi.org/10.1002/alz.14517 5. Sun Y et al. "Cognitive Activities, Lifestyle, and APOE4." Gerontology. 2023 https://doi.org/10.1159/000531109 6. Clinical Trial: ALA Nutrition for APOE4 MCI (NCT07392723) https://clinicaltrials.gov/study/NCT07392723

Originally published on YouTube on 27 April 2026. Original video: https://www.youtube.com/watch?v=oY_R_VOiwys Free guide: The APOE4 Woman's Guide https://thephoenix.community/guides/womens-guide Should APOE4 carriers consider hormone replacement therapy? I review research on HRT, menopause, testosterone and Alzheimer's risk, including the Women's Health Initiative, timing, formulation, APOE4-specific findings and the clinical trials discussed in this April 2026 recording. RESOURCES Apply to join Phoenix: https://apoe4.link/HRT Essential APOE4 Guide: https://apoe4.link/HRT-G Weekly Newsletter: https://apoe4.link/HRT-N CHAPTERS 00:00 Introduction 02:23 WHI Study What Was Studied vs What Wasn't 06:31 The Critical Window : Timing Is Everything 09:38 Why ApoE4 Changes Everything 14:19 Formulation Matters: Patches, Pills & Progesterone 19:09 Men, APOE4 & Testosterone 22:44 Clinical Trials Being Studied Right Now 23:10 Active Clinical Trials 26:19 5 Steps To Take This Week ORIGINAL LINKS AND REFERENCES Saleh et al. 2023 (EPAD): https://doi.org/10.1186/s13195-022-01121-5 Melville et al. 2025 (Lancet): https://doi.org/10.1016/j.lanhl.2025.100803 Nerattini et al. 2023: https://doi.org/10.3389/fnagi.2023.1260427 Whitmer et al. 2011: https://doi.org/10.1002/ana.22239 Kantarci et al. 2016 (KEEPS): https://doi.org/10.3233/JAD-160258 Wang/Brinton 2025: https://doi.org/10.3389/fnagi.2025.1632877 Blanchard et al. 2022 (Nature): https://doi.org/10.1038/s41586-022-05439-w Yeap & Flicker 2022: https://doi.org/10.1007/s11154-022-09728-7 Burkhardt et al. 2006: https://doi.org/10.1210/jc.2005-1072

Originally published on YouTube on 9 June 2026. Original video: https://www.youtube.com/watch?v=wbDdVGjvdFc Using diet, psyllium husk and ezetimibe, I lowered my ApoB nearly 40%, from 115 to about 70, without a statin. I walk through my lab panels, the changes I made and the evidence available at the time of this June 2026 recording, including what I was still watching next. RESOURCES Apply to join Phoenix: https://apoe4.link/Ezetimibe APOE4 Lipid Playbook: https://apoe4.link/EzetimibeG Weekly Newsletter: https://apoe4.link/EzetimibeN APOE4 Blood Work Blueprint: https://apoe4.link/EzetimibeB CHAPTERS 00:00 Introduction 03:18 Why APOE4 cholesterol is a different disease 07:29 My actual baseline 09:59 Lever 1: Diet (what I actually eat) 10:50 The Mediterranean pattern 11:35 The 4 moves I made 14:53 Lever 2: Psyllium husk (the underestimated one) 19:41 Lever 3: Ezetimibe (the standout lever, and why I skipped the statin) 28:25 2026 ACC/AHA guideline 29:35 The EZ-PAVE trial 31:05 SWEDEHEART registry results 32:37 The results 35:57 Honest caveats + what I'm watching next 38:58 My lipid blueprint for APOE4 carriers REFERENCES Fiber: Jovanovski 2018 PMID30239559; Gibb 2015 PMID26561625; Zhu 2024 PMID38688104; Ghavami 2023 PMID36796439; McRorie 2017 PMID27863994; Schoeneck 2021 PMID33762150; Brum 2018 PMID30078477; Juhász 2023 PMID36811560. APOE4: Liu 2025 PMID40855194; Husain 2021 PMC7925634; Mahley 2016 PMC4942259; Dunk 2022 PMID34958023; Sniderman 2019 PMC7369156. Ezetimibe: Nordestgaard 2025 PMID41059729 DOI10.1002/alz.70638; Ganne 2024 PMID39263528; Gorbunova 2024 PMC11927789; Rossi 2025 PMID41400788; Mark 2007 PMID17559752; Pandor 2009 PMID19141093; Ouchi 2019 PMID31434507; Garcia-Calvo 2005 PMID15928087; Cannon 2015 IMPROVE-IT; Awad 2018 PMID29396832; Lee 2021 PMC7935639. Statins: Rajan 2024 PMID38447103; Westphal Filho 2025 PMC11736423; Banach 2025 PMID40126455. 2026: ACC/AHA Guideline; Ez-PAVE NCT04626973; Leosdottir 2025 PMID40240093.

Originally published on YouTube on 6 June 2026. Original video: https://www.youtube.com/watch?v=V72QViR99hk Why does sleep matter so much for APOE4 carriers? I explain the research, how to distinguish physical sleep problems from stress, what to track, and the tools, supplements and devices discussed in the episode. The episode includes device recommendations and PHOENIX discount codes. The original device links are preserved below. RESOURCES Apply to join Phoenix: https://apoe4.link/Sleep APOE4 Sleep & Glymphatic Protocol: https://apoe4.link/SleepG Weekly Newsletter: https://apoe4.link/SleepN CHAPTERS 00:00 Introduction 01:43 WHY SLEEP MATTERS MORE FOR APOE4 CARRIERS 04:19 YOUR TARGET METRICS 06:29 DIAGNOSE FIRST - PHYSICAL ISSUES 08:34 Rule this out 09:43 DIAGNOSE - MENTAL AND STRESS ISSUES 11:11 Here's how to identify if stress is your issue 12:55 TOOLS AND DEVICES 16:45 OPTIMIZATIONS 18:19 Supplements That Have Evidence 20:25 TRACKING AND THE PHOENIX APP 22:05 Key Takeaways ORIGINAL LINKS AND REFERENCES Zenowell (vagus nerve stimulation): https://zenowell.com Neuronic (photobiomodulation): https://neuronic.com Andre C et al. (2024). "Reduced rapid eye movement sleep in late middle-aged and older apolipoprotein E e4 allele carriers." Sleep. https://pmc.ncbi.nlm.nih.gov/articles/PMC11236949/ Yu X et al. (2024). "Sleep and APOE-e4 have a synergistic effect on plasma biomarkers and longitudinal cognitive decline." CNS Neuroscience & Therapeutics. https://pmc.ncbi.nlm.nih.gov/articles/PMC10850800/ Lee H et al. (2015). "The Effect of Body Posture on Brain Glymphatic Transport." J Neuroscience. https://pmc.ncbi.nlm.nih.gov/articles/PMC4524974/ Hausenblas HA et al. (2024). "Magnesium-L-threonate improves sleep quality." Sleep Medicine X. https://pmc.ncbi.nlm.nih.gov/articles/PMC11381753/ Robbins R et al. (2024). "Accuracy of Three Commercial Wearable Devices for Sleep Tracking." Sensors. https://pmc.ncbi.nlm.nih.gov/articles/PMC11511193/